Key result
Pharmacological blockade of the renin-angiotensin-aldosterone system is a pivotal strategy in the treatment, control, and prevention of cardiovascular and chronic kidney diseases.
This review highlights the critical pathogenic role of the renin-angiotensin-aldosterone system in both cardiovascular and chronic kidney diseases, reinforcing the importance of its pharmacological blockade.
Reinforces RAAS blockade as standard in CV and CKD care; leaves open optimization of regimens in subgroups.
Cardiovascular disease (CVD) and chronic kidney disease (CKD) have become leading health problems worldwide. In addition, both conditions have relevant interrelatioships: cardiovascular disease may promote the development and progression of CKD, whereas CKD is a cardiovascular risk factor per se and potentiate the harmful effects of other cardiovascular risk factors. In addition, a critical common pathogenic and pathophysiologic factor in CVD and CKD is the renin-angiotensin-aldosterone system (RAAS). Moreover, from a therapeutic perspective, blockade of RAAS is a pivotal strategy in the treatment, control and prevention of CVD and CKD.
No takes yet. Share an insight, caveat, or question.
Heras et al. (2012) conducted a review in Cardiovascular disease and chronic kidney disease. Renin-angiotensin-aldosterone system (RAAS) blockade was evaluated. Pharmacological blockade of the renin-angiotensin-aldosterone system is a pivotal strategy in the treatment, control, and prevention of cardiovascular and chronic kidney diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: